january 13, 2021 engineering the medicines of tomorrow

Engineering the Medicines of TomorrowJean-Paul Kress, M.D., CEO

J.P. Morgan Healthcare Conference

January 13, 2021

2© MorphoSys

Forward-Looking Statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding tafasitamab’s ability to

treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab, including ongoing confirmatory trials, additional

interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial

performance of tafasitamab. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,”

“possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties,

which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any

historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if

MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking

statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding

risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys’ business, operations, strategy, goals and anticipated milestones, including its ongoing

and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or

future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the

further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys’ ability to obtain and maintain requisite regulatory approvals and to enroll

patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals

for tafasitamab as well as the commercial performance of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its

development programs and other risks indicated in the risk factors included in MorphoSys’ Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange

Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak

only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect

any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood

that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S.

Food and Drug Administration (FDA), European Medicines Agency (EMA) or any other regulatory authority (except for tafasitamab/Monjuvi® and guselkumab/Tremfya®).

There is no guarantee any investigational product will be approved.

2

3© MorphoSys

MorphoSys is an Emerging Leader in Hematology-Oncology

& Autoimmune Diseases

Commercial stage biopharma company with

Monjuvi® (tafasitamab-cxix) launched in the

U.S. as first product on the market

Robust late stage clinical pipeline developed by

MorphoSys and partners

Solid cash position of approx. € 1.3 billion1 and

continuous revenue and royalty stream

600+ employees in Germany and U.S.

1) Cash Position September 30, 2020: €987.2 m (pro-forma including the

convertible bond issuance in October: ~ € 1.3 billion)

3

4© MorphoSys

Focused on Execution

1) Monjuvi (tafasitamab-cxix) is approved by the U.S. FDA in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-

cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT) 2)

Cash Position September 30, 2020: €987.2 m (pro-forma including the convertible bond issuance in October: ~ € 1.3 billion)

Commercial Execution

Ensure continued successful launch of Monjuvi

Clinical Execution

Expand Monjuvi opportunity by initiating pivotal studies in 1st line

DLBCL and R/R FL

Global commercial and development collaboration with Incyte for

tafasitamab (Monjuvi®) which brought $900 million up front cash

(including equity investment)

Tafasitamab approved for r/r DLBCL in the U.S. in July 2020

Significantly strengthened balance sheet with EUR 1.3 billion2 in cash

and cash equivalents

2020 Was a Transformative Year

Focus on Execution in 2021

4

5

Products, Partnerships and Research Drive Stakeholder Value

Three drivers of value creation

© MorphoSys

Blockbuster medicine

Several additional

programs in mid and late-

stage development

First marketed product

Felzartamab in clinical

development for autoimmune

disease

Cutting-edge research

platforms and programs:

• Antibodies, T-cell engagers,

bispecifics

• Focus on oncology and

autoimmune diseases

PRODUCT REVENUEfrom MorphoSys

commercialization

ROYALTY REVENUEfrom partners

RESEARCH PLATFORMScreate opportunities to drive

long-term growth

5

6© MorphoSys

Robust Late-Stage Clinical Pipeline

Program Partner Target Disease area Ph 1 Ph 2 Ph 3 Market

Tafasitamab Incyte1) CD19

r/r DLBCL

1L DLBCL

r/r FL / MZL

Felzartamab - CD38 Autoimmune (M-PLACE)

1) Joint development globally and co-commercialization in the U.S., Incyte has exclusive commercialization rights outside the U.S. 2) For development in China, Hong Kong, Macao, Taiwan

Pipeline products are under clinical investigation and have not been proven to be safe or effective. DLBCL: diffuse large B-cell lymphoma; FL. Follicular lymphoma; r/r: relapsed/refractory

Tremfya® Janssen IL-23 p19Psoriasis

Psoriatic Arthritis

Otilimab GSK GM-CSF

Rheumatoid Arthritis (ContRAst 1-3)

Severe Pulmonary COVID-19 Related

Disease (OSCAR)

Gantenerumab Roche Amyloid-b Alzheimers Disease (Graduate 1 + 2)

FelzartamabI-Mab

Biopharma2) CD38 Multiple Myeloma

Product revenue from MorphoSys commercialization

Royalty revenue from partners

6

7

tafasitamab

© MorphoSys7

8© MorphoSys

Tafasitamab Received FDA Approval Mid-2020

Compelling tafasitamab profile

Potential best-in-class anti-CD19 antibody for the treatment of

certain hematological malignancies

First and only approved drug in the U.S. for 2L+ adult NTE DLBCL

in combination with lenalidomide

Global commercial partnership with Incyte

• Co-commercialization in the U.S., MorphoSys books revenues

• Incyte responsible for commercialization outside of the U.S.

Multiple studies ongoing to establish tafasitamab as potential

backbone treatment in DLBCL and to expand into other indications

8

9© MorphoSys

Addressing High Unmet Medical Need

For r/r DLBCL patients in 2L+, not eligible for

autologous stem cell transplant, MONJUVI® +

lenalidomide …

Efficacy

… is the first and only 2L+ therapy resulting in

patients having complete and durable responses

Safety & Tolerability

… has a safety & tolerability profile that supports

treatment to disease progression2

Accessibility

… can be administered in community and academic

settings

MONJUVI®, in combination with lenalidomide, is

indicated for the treatment of adult patients with

relapsed or refractory diffuse large B-cell lymphoma

(DLBCL) not otherwise specified, including DLBCL

arising from low grade lymphoma, and who are not

eligible for autologous stem cell transplant (ASCT).1

Indication

• Best overall response rate 55% (43%-67%)

• Complete response rate 37%

• Median duration of response 21.7 (0,24) months

1This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit

in a confirmatory trial(s). 2 The most serious AEs included infusion-related reactions, serious or severe myelosuppression (including neutropenia), thrombocytopenia, infections and embryo-fetal

toxicity. Permanent discontinuation of MONJUVI or lenalidomide due to an adverse reaction occurred in 25% of patients and permanent discontinuation of MONJUVI due to an adverse reaction

occurred in 15%. USPI https://www.monjuvi.com/pi/monjuvi-pi.pdf

Key efficacy data1

9

https://www.monjuvi.com/pi/monjuvi-pi.pdf

10

Continued momentum in account adoption

• >250 sites of care ordered through October

• 80% of accounts have reordered

• Growing momentum in the community setting

First sales booked in Q3

• $5M Net Sales in Q3 from dosing of first patient on

August 13 through 30 September (~7 weeks of sales)

10,000 patients in the U.S. per year eligible for

treatment with Monjuvi

© MorphoSys

Monjuvi’s® Potential in the U.S. Market

2nd Line

NTE

5,000

2nd line patients

axicabtagene ciloleucel

tisagenlecleucel

polatuzumab

selinexor

3rd Line+

NTE

5,000

3rd+line patients

Early Days of Launch Market Opportunity

10

11

Treatment with Tafa/Len Combination Results in Durable Responses

L-MIND – long-term follow-up data (≥24 months)

Salles et al., EHA 2020

Tafa+ LEN

80 77 69 64 54 37 1345Number of patients at risk

1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1

0 1 3 6 12 24 3618

Pro

bablity

of

overa

ll s

urv

ival

Time (months)

Censored

Median OS: 31.6 months (95% CI: 18.3-NR)

Patients with CR: >90% alive after 2 years

Time to event end point including OS are difficult to interpret in a

single arm study.

Median DoR: 34.6 months (95% CI: 26.1–34.6)

Patients with CR: >85% responding after 2 years

1.0 0.9

Pro

port

ion o

f pati

ents

in r

em

issi

on 0.8

0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0

0 1 3 6 12 24 3018

Time (months)

Number of patients at risk 14 10 13 5 4 2 1 1

CR 33 30 32 29 23 22 11 Censored

47 40 45 34 27 24 12 98

PR

PR/CR

© MorphoSys11

12

• Need to improve the efficacy of R-CHOP

• Strong synergies between tafasitamab +

lenalidomide in r/r DLBCL

Combining Tafasitamab + Len / R-CHOP in 1L DLBCL

Working to address unmet need in frontline DLBCL

• 30,000 patients newly diagnosed in the U.S. per year

• High risk patients (IPI 3-5) with highest unmet

medical need,~50% of these patients do not respond to

R-CHOP or relapse

Unmet need in 1L DLBCL

Rationale supporting tafa/len combination

Screening

R-CHOP + tafasitamab + lenalidomide (75 years, stage IV, IPI 4)

After 3 cycles (CR)

THIS IS A SINGLE PATIENT RESPONSE WHICH IS PROVIDED FOR ILLUSTRATION

ONLY. THE PRODUCT IS IN DEVELOPMENT IN THIS INDICATION AND THIS

ILLUSTRATION DOES NOT GUARANTEE ALL PATIENTS WILL OBSERVE THE SAME

EFFICACY NOR HEALTH AUTHORITIES APPROVAL

© MorphoSys12

13

Pivotal phase 3 study in 1L DLBCL expected to start in H1 2021

Ambition to Improve Cure Rates in DLBCL

firstMIND study• n = 60 patients

Efficacy & Safety:

• ORR 91.1%

• Interim response assessments after 3 cycles,

both arms combined

Safety:

• No new safety signals

• No patients discontinued treatment due to AEs

Pivotal phase 3 study:

• tafa + len + R-CHOP vs. R-CHOP

• n = 900 patients

Key factors built into study:

• Addition of two synergistic drugs to R-CHOP

• Time to treatment ≤ 28 days

• High risk patients IPI 3-5

Encouraging phase 1b data in 1L DLBCL Paving the way for the start of a pivotal trial

© MorphoSys13

14

Phase 3 pivotal trial

• N = 600 patients

• tafasitamab/len + R (R2) vs R2

• Study start expected in 2021

• Aim of study: significant

prolongation of PFS

• Orphan drug designation in FL

granted by the FDA

Combining Tafasitamab + R2 in Indolent Lymphoma

Phase 3 study in r/r FL and r/r MZL expected to start in 2021

Unmet need in follicular

lymphoma

Rationale and datasupporting tafa/len combination

Development path forward in

indolent lymphoma

Tafasitamab:

• Early signs of activity observed

with tafasitamab monotherapy

Lenalidomide:

• Approved for the treatment of

FL and MZL

Building on the potential synergy

of tafasitamab and lenalidomide

1st line

~11,000

drug-treated patients1)

~1,600 deaths

per year in the U.S.2)

FL is the second most common

subtype of NHL

© MorphoSys

2nd/3rd/4th line (r/r)

~10,000

drug-treated patients1)

1) drug-treated patients in the US, source DRG, number of patients in 2021 2) source SEER database, number of patients in 20201 FL: follicular lymphoma MZL: marginal zone lymphoma

14

15

Combining Tafasitamab with New Agents

• Investigating tafasitamab in

combination with Xencor’s CD20xCD3

bispecific plamotamab

• Clinical development in r/r DLBCL, 1L

DLBCL and FL to be sponsored by Xencor

• First clinical trial to start in 2021

© MorphoSys

tafasitamab

Target: CD19

MoA: ADCC, ADCP

plamotamab

Target: CD20

MoA: T cell engagement

Exploring additional treatment options for patients with non-Hodgkin lymphomas

15

16

Tafasitamab as Backbone in DLBCL and Beyond

© MorphoSys

Establish Monjuvi-LEN as standard of care in r/r DLBCL

Develop Monjuvi as backbone in DLBCL and beyond

Expand indication into other NHL types

Incre

ase

valu

e t

hro

ugh

life

cycle

managem

ent

16

17

Multiple opportunities to address significant unmet needs in non-Hodgkin lymphomas

© MorphoSys

Broad Tafasitamab Clinical Program to Maximize Value for Patients

Study Indication Status Ph 1 Ph 2 Ph 3 Market

L-MIND r/r DLBCL FDA approved in 2L

B-MIND r/r DLBCL Ongoing

firstMIND 1L DLBCL Ongoing

frontMIND 1L DLBCL Trial initiation expected H1 2021

inMIND r/r FL / MZL Trial initiation expected H1 2021

Parsaclisib1)

combination

r/r B-cell

malignanciesTrial initiation expected 2021

CD20xCD3

combination

r/r DLBCL

1L DLBCL

r/r FL

First trial expected to start 2021Studies sponsored

by Xencor

J-MIND (Japan)r/r DLBCL

and othersOngoing

1) Parsaclisib: PI3Kd inhibitor owned by Incyte; The clinical development program does not guarantee a regulatory approval; r/r: relapsed or refractory; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma;

MZL: marginal zone lymphoma

17

19© MorphoSys

Exploring Felzartamab (MOR202) in Autoimmune Diseases

Anti-CD20,-CD19,-CD40 (L),-BAFF

Anti-FcRn,

Complement-

inhibitorsAnti-CD38 (Felza)

Earlier

B-cell

stages

Activated

B cell

Plasma-blastShort/ Long-lived

Plasma cell

Inflammation/

Organ damage

Specific targeting of autoantibody producing

plasma cells

Clinical development plan:

- PoC data from M-PLACE phase 1b/2a

study expected in H1 2021

- Ready to broaden clinical development

CD38 antibody in clinical development

First indication in development:

aMN - membranous nephropathy

- 10,000 eligible patients in the U.S. per year

- High unmet need, 30%–40% of patients progress

to end-stage renal disease (ESRD) within 5–15

years1)

Targeting CD38 – excellent way to prevent auto-Abs

First PoC data in membranous nephropathy expected in H1 2021

1) Chen et al. 2014

19

21

Designed to create combinatorial flexibility to the benefit of our patients

© MorphoSys

MOR Research Technology Platforms to Expand Pipeline

• CyCAT® = Cytotoxic Cell Activation at Tumor

• Innovative split-CD3 effector platform

OkapY™ = Innovative 2+1 TCE format

Antibody discovery platformHuCAL®, Ylanthia®, Slonomics®

Fill own pipeline

with focus on hematology-

oncology and solid cancer

Dual Targeting T-cell engagers

T-cell engagers (TCEs)

Bispecifics

Advancing proprietary

technology platforms

Antibody engineering and BiSpecific platforms OkapYTM, CyCAT®

21

23© MorphoSys

Partnered Assets Have Potential to Generate Increasing Royalty Stream

37-42 million EUR in royalties for 2020 for Tremfya, significant growth potential

Tremfya

(IL-23)

Psoriasis

Otilimab

(GM-CSF)

Rheumatoid arthritis

Gantenerumab

(amyloid-beta)

Alzheimers disease

Several programs with

different partners:

Novartis, Mereo,

Janssen, Bayer

Tremfya

(IL-23)

PsA

Felzartamab

(CD38)

Multiple myeloma

Guselkumab

(IL-23)

Crohns disease

Ulcerative colitis

MOR210

(C5aR)

Oncology

Several programs with

different partners:

Novartis, Ultragenyx, Pfizer,

BI, Anthos Therapeutics,

Shandong Fontacea

Ianalumab

(BAFF-R)

SLE, IPF

Royalties$$

Phase I Phase II Phase III Market

Milestones

23

24© MorphoSys

Expected Newsflow 2021 and Beyond

Selected programs

Tafasitamab – inMIND

Pivotal Study Start

r/r FL

Tafasitamab - frontMIND

Pivotal Study Start

1L DLBCL

Tafasitamab – Plamotamab

Start of combo studyr/r B-cell malignancies

Felzartamab - M-PLACE

Phase 1/2 data

aMN

Otilimab - OSCAR

Data from COVID-19 patients

Tafasitamab – frontMIND

Potential Regulatory Filing

1L DLBCL

Tafasitamab – inMIND

Potential Regulatory Filing

r/r FL

Otilimab – ContRAst

Phase 3 data

Rheumatoid Arthritis

Gantenerumab – GRADUATE

Phase 3 data

Alzheimer‘s Disease

Tafasitamab – B-MIND

Phase 3 data

r/r DLBCL

Tafasitamab

Expected European Approval

r/r DLBCL

Felzartamab – I-MAB

BLA for China

3L Multiple Myeloma

Tafasitamab – L-MIND

≥4 year long-term follow

up data

Tafasitamab – L-MIND

≥3 year long-term follow up data

2021 2021 continued 2022 Beyond 2022

Tafasitamab – Parsaclisib

Start of combo studyr/r B-cell malignancies

24

25© MorphoSys

In Closing. . .

Well-positioned for the future

Ongoing execution of Monjuvi launch in the U.S.

Pivotal studies start in H1 2021 to potentially

expand tafasitamab opportunity to

1L DLBCL and r/r FL

Well capitalized to execute on our growth

strategy

Robust late stage pipeline

25

The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S. Food and Drug Administration (FDA),

European Medicine Agency (EMA) or any other regulatory authority (except for tafasitamab/Monjuvi® and guselkumab/Tremfya®). HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®,

Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma®, LanthioPep®, ENFORCER® and Monjuvi® are trademarks of the MorphoSys Group. Tremfya® is a trademark of Janssen Biotech, Inc. XmAb® is

a trademark of Xencor, Inc.

www.morphosys.com

Thank You

Thank You

CORP-US-00049 26

january 13, 2021 engineering the medicines of tomorrow

Documents